课题基金 / 基金详情

Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion

Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion
评估直接抗病毒治疗获取政策对慢性丙型肝炎患病率和未确诊比例的影响
批准号:
475136
负责人:
Wong William Wai Lun
金额:
$10.93万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2022
资助国家:
加拿大
项目状态:
已结题
起止时间:
2022-10-01 至 2023-10-01

项目摘要

项目成果

Wong William Wai Lun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hepatitis C virus (HCV) is one of the most burdensome infection and one of the most expensive infectious disease to prevent and treat. HCV infection can cause chronic infection of the liver (i.e. chronic hepatitis C (CHC)), that is silent for 20-30 years
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards establishing accurate estimates of national chronic hepatitis B prevalence and undiagnosed proportion in Canada
  • 批准号:
    488763
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2023
  • 负责人:
    Wong William Wai Lun
  • 依托单位:
Developing policy models for sexually transmitted and blood-borne infection: integrating best evidence of effectiveness, safety, cost, and patient preferences
  • 批准号:
    499040
  • 项目类别:
    Salary Programs
  • 资助金额:
    $83.78万
  • 财政年份:
    2023
  • 负责人:
    Wong William Wai Lun
  • 依托单位:
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
  • 批准号:
    456739
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Wong William Wai Lun
  • 依托单位:
Estimating chronic hepatitis B prevalence and the undiagnosed proportion in Canada using health administrative data
  • 批准号:
    453432
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2021
  • 负责人:
    Wong William Wai Lun
  • 依托单位:
海外基金